hit counter
CymaBay Therapeutics, Inc. (CBAY) Stock News Sentiment & Price - Sentifly
CBAY - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



CymaBay Therapeutics, Inc. (CBAY)

USA
Biotechnology
NASDAQ
CBAY Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CBAY Latest news
Seeking Alpha
Neutral
CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2021 Results - Earnings Call Transcript
2021-08-12 22:21

CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2021 Results - Earnings Call Transcript

GlobeNewsWire
Neutral
CymaBay Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update
2021-08-12 16:06

Secured up to $100 million of additional development funding through a non-dilutive financing transaction with Abingworth

GlobeNewsWire
Neutral
CymaBay Therapeutics to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021
2021-08-05 16:01

NEWARK, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, August 12, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2021 and to provide a business update.

Benzinga
Positive
CymaBay Secures $100M Non-Dilutive Funding To Fund Seladelpar Development Program
2021-08-02 10:29

CymaBay Therapeutics Inc (NASDAQ: CBAY) has received $100 million in non-dilutive financing from Abingworth to fund the Phase 3 development program for seladelpar in primary biliary cholangitis (PBC). Under the terms of the transaction, CymaBay will receive up to $100 million of seladelpar development costs, of which $75 million will be received in three installments over approximately six months.

GlobeNewsWire
Neutral
CymaBay Announces $100 Million Non-Dilutive Financing with Abingworth
2021-08-02 08:00

Risk-sharing agreement with Abingworth will fund seladelpar Phase 3 development program for PBC

Zacks Investment Research
Negative
New Strong Sell Stocks for July 20th
2021-07-20 10:52

AEVA, BIDU, CBAY, DRNA and RACE have been added to the Zacks Rank #5 (Strong Sell) List on July 20, 2021.

Seeking Alpha
Neutral
Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q1 2021 Results - Earnings Call Transcript
2021-05-13 23:00

Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q1 2021 Results - Earnings Call Transcript

GlobeNewsWire
Neutral
CymaBay Reports First Quarter 2021 Financial Results and Provides Corporate Update
2021-05-13 16:06

Highly experienced executives, Dr. Dennis Kim as Chief Medical Officer and Lewis Stuart as Chief Commercial Officer, strengthen the management team

GlobeNewsWire
Neutral
CymaBay Names Lewis Stuart Chief Commercial Officer
2021-05-10 08:00

Proven Leader in Building Commercial Organizations to Prepare Markets and Deliver Successful Product Launches  Planning for Seladelpar Launch as it Completes Development and Regulatory Submissions

GlobeNewsWire
Neutral
CymaBay Appoints Thomas Wiggans and Janet Dorling to Board of Directors
2021-04-05 08:00

NEWARK, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of biopharma veteran Thomas Wiggans and commercial leader Janet Dorling to its Board of Directors. Concurrently with these appointments, CymaBay announced that Paul F. Truex has resigned from the Board of Directors effective as of April 1, 2021 to focus on his new role as Chief Executive Officer of LQT Therapeutics.

Loading more news...